Cyclerion Therapeutics
Cambridge · Founded 2019
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Company Facts
- Founded: 2019
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $222.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2023)
- Ticker: nasdaq:CYCN
- Website: cyclerion.com
- Phone: (857) 327-8778
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cyclerion-therapeutics-74101 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.